drugset / Trial / NCT00564226

SSR240600C Treatment in Women With Overactive Bladder

NCT00564226

Phase 2 Completed 345 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.

Timeline

Start
2007-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BURAPITANT Small molecule Oral
Comparator Tolterodine Small molecule Oral

Indications